Drug Database
AN

antithrombin III (Neuart)

✓ Approved

Mitsubishi Tanabe Pharma Corporation · SERPINC1 · 细胞治疗

什么是 antithrombin III?

antithrombin III 是一种细胞治疗,由Mitsubishi Tanabe Pharma Corporation研发。该药已获批,用于治疗相关适应症。

药物档案

商品名Neuart
公司Mitsubishi Tanabe Pharma Corporation
药物类别细胞治疗
分子靶点SERPINC1
状态Approved

作用机制

分子靶点

antithrombin III 作用于 1 个分子靶点:

SERPINC1serpin family C member 1 (ATIII, AT3D)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

antithrombin III 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersThrombosis✓ Approved

相关研究文献

PubMedLight, science & applications2026-08-08

Highly efficient dual-channel doublet emission in lanthanide cerium(III) complex.

Li Yujia Y, Fang Peiyu P, Xiong Zeyou Z, Zheng Jiayin J et al.

Dual-channel luminescent materials are attractive due to their unique electronic structures and potential applications in various fields. Different from traditional dual-channel emitters with closed-shell structure showing singlet fluorescence and/or triplet phosphorescence, we demonstrate herein dual-channel cerium(III) complexes with open-shell structure showing doublet 5d-4f emission from the central Ce(III) ion. By systematically designing and studying a series of cerium(III) complexes Ce(Tp4Me)(Bp4Me)2, Ce(Tp4Me)2(Bp4Me) and Ce(Tp4R)3 (R = Me, Cl, I) with gradually varied coordination numbers from seven to eight and nine, respectively, it is found that the nine-coordinated complexes Ce(Tp4R)3 showed crowded coordination environments and longer coordination bonds, which underwent a coordination structural relaxation after high energy light excitation, resulting in a new channel emission. This work demonstrates an intriguing dual-channel doublet emission phenomenon in lanthanide Ce(III) complexes and will inspire new insights both into the design of novel lanthanide-based luminescent materials and dual-channel luminescent materials.

PMID 42567858
阅读全文 →
PubMedFrontiers in endocrinology2026-08-08

Editorial: Digital technology in the management and prevention of diabetes, volume III.

Nag Pushpita P, Shen Yun Y, Zou Xiantong X, Hu Gang G

PMID 42568354
阅读全文 →
PubMedFrontiers in pharmacology2026-08-08

Editorial: Increasing importance of patients-generated real world data for healthcare policy decisions about medicinal products: volume III.

Choon Wai Yee WY, Lee Kenneth K C KKC, Scuffham Paul P, Li Shu Chuen SC et al.

PMID 42568563
阅读全文 →
PubMedOrthopaedics & traumatology, surgery & research : OTSR2026-08-08

Sub-emergency versus emergency or delayed free flap coverage for Gustilo III upper limb fractures: With reduced infection, enhanced limb salvage, and improved functional recovery.

Zhou Feiya F, Jiang Wenjing W, Liu Huachen H, Wang Jinwu J et al.

Gustilo type III open fractures of the upper extremity present severe soft‑tissue and bony injuries. Free flap reconstruction is standard, but the optimal timing remains debated. This study aimed to assess the association between timing of coverage and postoperative infection rates. In this observational cohort study, 85 patients with upper limb Gustilo III fractures (2018-2024) were allocated to three groups based on clinical decision: emergency (same anesthetic, n = 25), sub‑emergency (within 72 h, n = 26), or delayed (>72 h, n = 34). Demographics, perioperative data, and complications were analyzed. Multivariable logistic regression was performed but limited by low event numbers. Baseline characteristics were comparable except for higher Injury Severity Score (ISS) in the delayed group (p = 0.001). Infection rates were 4.0% (1/25) in emergency, 3.8% (1/26) in sub‑emergency, and 29.4% (10/34) in delayed group (p = 0.001). Osteomyelitis, flap necrosis, and bone defects occurred almost exclusively in the delayed group. Multivariable analysis (13 total infections) did not identify timing as an independent predictor (p = 0.831); higher ISS, longer operative time, and extended hospital stay showed trends but were not statistically significant. Functional recovery (QuickDASH, SF‑12 PCS) was superior in both early groups. Patient satisfaction was highest in the sub‑emergency group. In this observational study, free flap coverage beyond 72 h was associated with higher unadjusted infection rates; however, this finding cannot be interpreted causally due to severe confounding-by-indication, as the delayed cohort sustained significantly higher baseline trauma severity (ISS). Emergency and sub-emergency (<72 h) coverage demonstrated comparable favorable outcomes, suggesting that the sub-emergency window represents a safe, logistically advantageous alternative LEVEL OF EVIDENCE: III; Therapeutic.

PMID 42551735
阅读全文 →
PubMedJournal of the American Pharmacists Association : JAPhA2026-08-08

Marijuana scheduling snapshot: A rapid 50-state and D.C. survey.

Smith Zachary D ZD, Barenie Rachel E RE

Marijuana is a schedule I controlled substance under federal law, but the Drug Enforcement Administration has published a proposed rule to reschedule it to schedule III at the federal level. This may create an even more complex regulatory landscape for the drug, with potentially ongoing conflicts between federal and state law. To evaluate the current scheduling of marijuana in the United States. In January 2026, two researchers independently conducted a 50-state survey to identify the schedule of marijuana in all 50 states and D.C. Westlaw, a legal database, was used to conduct searches in each state using the following search terms: "marijuana, "controlled substance," "schedule," "cannabis," and "marihuana." Most states listed marijuana as a schedule I controlled substance (n=33; 65%), which is the most restrictive schedule and consistent with current federal law. A total of nine (18%) states did not schedule marijuana. A total of nine (18%) states included marijuana in another schedule or classification system, with two (4%) states having already adopted schedule III. This review of state laws highlights implications of potentially rescheduling marijuana to schedule III, including three post-change scenarios: (1) state law is stricter than federal, (2) federal law remains stricter, and (3) automatic change in schedule when state law defers to federal. This will likely create more regulatory complexity immediately post-change, and pharmacists must be mindful of their state's laws in practice to ensure compliance, particularly for states that become the stricter law on the topic.

PMID 42567447
阅读全文 →
PubMedJournal of the American Heart Association2026-08-08

Utility of Prognostic Staging Systems in Transthyretin Amyloidosis Cardiomyopathy in the Era of Available Disease-Modifying Treatment.

Skov Jens K JK, Clemmensen Tor S TS, Scott Christopher G CG, Abou Ezzedine Omar F OF et al.

Prognostic staging systems in transthyretin amyloid (ATTR) cardiomyopathy were developed before the introduction of disease-modifying treatment. We therefore evaluated contemporary risk stratification according to different staging systems in patients with ATTR cardiomyopathy. All patients with newly diagnosed ATTR cardiomyopathy and baseline biomarker measurements from 2019 to 2023 were included from Mayo Clinic, Rochester, MN. Prognostic outcomes were calculated with Kaplan-Meier analysis for 3e staging systems in the main analysis: the National Amyloidosis Centre (NAC) staging system; a modified Mayo staging system using hsTNT (high-sensitivity troponin T) cutoff >65 ng/L; the extended NAC model with a fourth stage (NT-proBNP [N-terminal pro-B-type natriuretic peptide] >10 000 ng/L). The study population consisted of 441 patients with a median age of 76 years, 93% were men, 85% were initiated on tafamidis, and 94% had wild-type ATTR. Median follow-up was 3.4 years, and 109 deaths occurred during follow-up. The 3-year survival for the Mayo stages were 92.3% (88.7-95.9) for stage I, 71.6% (63.0-81.3) for stage II, and 43.5% (32.4-58.5) for stage III. For the NAC system, 3-year survival were 92.0% (89.0-95.7), 67.5% (59.0-77.3), and 47.0% (34.7-63.5) for stages I, II, and III, respectively. The 3-year survival by the extended NAC system was 92.0 (69.0-79.2), 69.0% (60.1-79.2), 53.2% (39.9-70.8) and 34.4% (17.4-68.0) for stages I, II, III, and IV, respectively. In a contemporary cohort of patients with ATTR cardiomyopathy, the NAC and modified Mayo staging systems remained equally effective in delineating clinically meaningful prognostic groups, whereas the extended NAC system identified a stage IV subgroup with high mortality.

PMID 42568056
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多antithrombin III